GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley Sells 922 Shares

GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley sold 922 shares of the firm’s stock in a transaction on Monday, March 10th. The stock was sold at an average price of $94.72, for a total transaction of $87,331.84. Following the transaction, the chief financial officer now directly owns 5,446 shares of the company’s stock, valued at approximately $515,845.12. This trade represents a 14.48 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Kevin Feeley also recently made the following trade(s):

• On Wednesday, January 29th, Kevin Feeley sold 275 shares of GeneDx stock. The stock was sold at an average price of $78.48, for a total transaction of $21,582.00.
• On Tuesday, January 7th, Kevin Feeley sold 35,506 shares of GeneDx stock. The stock was sold at an average price of $93.82, for a total transaction of $3,331,172.92.
• On Thursday, January 2nd, Kevin Feeley sold 1,430 shares of GeneDx stock. The stock was sold at an average price of $76.04, for a total transaction of $108,737.20.
• On Monday, December 16th, Kevin Feeley sold 3,728 shares of GeneDx stock. The shares were sold at an average price of $76.75, for a total transaction of $286,124.00.

GeneDx Stock Down 2.8 %

WGS stock opened at $87.17 on Wednesday. The stock has a market capitalization of $2.45 billion, a P/E ratio of -44.47 and a beta of 1.90. The firm has a 50-day simple moving average of $83.71 and a 200-day simple moving average of $68.68. The company has a quick ratio of 2.27, a current ratio of 2.40 and a debt-to-equity ratio of 0.25. GeneDx Holdings Corp. has a 52 week low of $7.72 and a 52 week high of $115.60.

GeneDx (NASDAQ:WGS) last released its earnings results on Tuesday, February 18th. The company reported $0.70 EPS for the quarter, topping analysts’ consensus estimates of $0.04 by $0.66. The business had revenue of $95.64 million during the quarter, compared to analysts’ expectations of $82.24 million. GeneDx had a negative net margin of 17.12% and a positive return on equity of 3.33%. Equities analysts forecast that GeneDx Holdings Corp. will post 0.97 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on WGS shares. The Goldman Sachs Group lifted their price objective on shares of GeneDx from $70.00 to $80.00 and gave the company a “neutral” rating in a report on Wednesday, February 19th. TD Cowen lifted their price objective on shares of GeneDx from $75.00 to $118.00 and gave the company a “buy” rating in a report on Tuesday, January 7th. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $72.33.

Hedge Funds Weigh In On GeneDx

A number of institutional investors and hedge funds have recently bought and sold shares of the business. MCF Advisors LLC boosted its position in GeneDx by 107.7% during the fourth quarter. MCF Advisors LLC now owns 351 shares of the company’s stock worth $27,000 after acquiring an additional 182 shares during the last quarter. Sterling Capital Management LLC boosted its position in GeneDx by 877.8% during the fourth quarter. Sterling Capital Management LLC now owns 352 shares of the company’s stock worth $27,000 after acquiring an additional 316 shares during the last quarter. Global Retirement Partners LLC acquired a new position in GeneDx during the fourth quarter worth about $28,000. MetLife Investment Management LLC boosted its position in GeneDx by 6.2% during the fourth quarter. MetLife Investment Management LLC now owns 7,750 shares of the company’s stock worth $596,000 after acquiring an additional 453 shares during the last quarter. Finally, Lazard Asset Management LLC acquired a new position in GeneDx in the 4th quarter valued at about $35,000. 61.72% of the stock is currently owned by institutional investors and hedge funds.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.